LEGAL ASPECTS OF DIRECT-TO-CONSUMER GENETIC TESTS.
Journal Title: Journal of IMAB - Annual Proceeding (Scientific Papers) - Year 2011, Vol 17, Issue 1
Abstract
Genetic testing is a type of medical test that identifies changes in chromosomes, genes, or proteins. Most of the time, testing is used to find changes that are associated with inherited disorders. The results of a genetic test can confirm or rule out a suspected genetic condition or help determine a person’s chance of developing or passing on a genetic disorder. The main difference between direct-to-consumer genetic testing and the standard genetic testing is the way informational support is provided in internet offers of testing. Counselling may be offered as an additional special service at extra costs and at the customer's request. It may also be that a recommendation or at least an offer is given for the customer to contact a doctor or health practitioner from the company via phone for counselling. In a liberal society the fundamental individual rights can be considered to include access to medical treatment and diagnostics that may be helpful for improving one's health condition or that can help an individual make decisions regarding life style and health. At the European level, there are no binding legal regulations that specifically apply for genetic testing. In some European counties, national laws, require a responsible medical person to be involved before a genetic test is provided. The Convention on Human Rights and Biomedicine was adopted by the Committee of Ministers on 19 November 1996, while an Additional Protocol to the Convention, concerning Genetic Testing for Health Purposes, was adopted by the Committee of Ministers on 7 May 2008. Direct-to-consumer genetic testing is closely watched by the community of medical genetics and counsellors, and the EU funded Eurogentest Network of Excellence. In 2010, the European Society of Human Genetics has releaseda statement on direct-to-consumer gene testing for health-related purposes. The European Society of Human Genetics is concerned about the way in which commercial companies are currently introducing genetic tests into the market outside of the scope of the traditional healthcare system.
Authors and Affiliations
Mariela Yaneva – Deliverska
Keywords
Related Articles
- EP ID EP131033
- DOI 10.5272/jimab.2011171.135
- Views 104
- Downloads 0
MULTIFOCAL GLIOBLASTOMA MULTIFORME PRECEDED BY A GEMISTOCYTIC ASTROCYTOMA AND DYSREGULATED IMMUNE RESPONSE.
Glioblastoma multiforme (GBM) is known to be the most common malignant form of astroglial brain tumors. The etiology, cellular and molecular pathogenic mechanisms remain unclear to a great extent. Recent research indicat...
A CURRENT 4-YEARS RETROSPECTIVE SURVEY OF 64 SURGICALLY TREATED ZYGOMA COMPLEX FRACTURES IN DEPARTMENT OF MAXILLO-FACIAL SURGERY, UNIVERSITY HOSPITAL ‘ST. ANNA’, SOFIA, BULGARIA.
Purpose: The goal of this material was to be an example of the complications that can occur in cases of zygoma fractures and to draw the attention of the clinicians to the need of accurate diagnose and early treatm...
FLOWCYTOMETRY IN LEPTOSPIROSIS
Differential count of leucocytes and six lymphocyte populations and subpopulations were investigated by flow cytometry in fourteen cases with leptospirosis. Marked granulocytosis and lymphopenia were found in 100%. The p...
DELAYED FDG-PET/CT IMAGES IN PATIENTS WITH BRAIN TUMORS - IMPACT ON VISUAL AND SEMIQUANTITATIVE ASSESSMENT
Background: Despite the extensive use of FDG-PET/CT its role in brain tumor assessment remains controversial mostly because of the physiologically high brain uptake which easily obscures pathological processes. The...
PLASMA EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND BASIC FIBROBLAST GROWTH FACTOR (bFGF) IN PATIENTS WITH BRAIN TUMORS.
OBJECTIVE: Angiogenesis and angiogenic growth factors are of basic importance in the development and progresion of brain tumours. The purpose of the study was to evaluate the plasma levels of two angiogenic factors...